A new wave of US biosimilar patent disputes begins
After a lull in biologic versus imitator disputes, Regeneron has sued Mylan and more litigation is likely to follow
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.